NDA for Luye Pharma's Rivastigmine Twice Weekly Transdermal Patch Filed in Japan for Treating Alzheimer's Dementia.

Luye Pharma Group has announced that its partner Towa Pharmaceutical Co., Ltd. has filed a New Drug Application (NDA) in Japan for the Rivastigmine Twice Weekly Transdermal Patch, which is used to treat mild to moderate dementia associated with Alzheimer's disease. The drug was developed by Luye Pharma and utilizes an innovative drug delivery system. The NDA was filed based on the positive results of a Phase 3 clinical trial. Alzheimer's disease is a neurodegenerative disease that causes memory decline, and it is the most common type of dementia. The Rivastigmine Twice Weekly Transdermal Patch is administered less frequently than other available patches, which may improve medication adherence. Luye Pharma is seeking global approval for the product and has already received approval in multiple European countries and China. [Extracted from the article]